2-(4-pyridyl)-1,3-benzoxazole-6-carboxylic acid | 884849-56-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 2-(4-pyridyl)-1,3-benzoxazole-6-carboxylic acid
• 英文别名: 2-pyridin-4-yl-benzooxazole-6-carboxylic acid；2-Pyridin-4-yl-1,3-benzoxazole-6-carboxylic acid
• CAS: 884849-56-3
• 化学式: C₁₃H₈N₂O₃
• 分子量: 240.218
• InChiKey: SYQOLYPNYWFVCZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  76.2
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(4-pyridyl)-1,3-benzoxazole-6-carboxylic acid 、 在 三甲基氯硅烷 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 三乙胺 、 sodium iodide 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 2.0h， 生成 N-[(2R,3S)-3-amino-2-hydroxy-4-phenylbutyl]-N-(2-methylpropyl)-2-pyridin-4-yl-1,3-benzoxazole-6-carboxamide
  参考文献：
  名称：

  Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors

  摘要：

  A new class of benzoxazole and benzothiazole amide derivatives exhibiting potent CYP3A4 inhibiting properties was identified. Extensive lead optimization was aimed at improving the CYP3A4 inhibitory properties as well as overall ADME profile of these amide derivatives. This led to the identification of thiazol-5-ylmethyl (2S,3R)-4-(2-(ethyl(methyl) amino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate (C1) as a lead candidate for this class. This compound together with structurally similar analogues demonstrated excellent 'boosting' properties when tested in dogs. These findings warrant further evaluation of their properties in an effort to identify valuable alternatives to Ritonavir as pharmacokinetic enhancers. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.022
• 作为产物：
  描述：

  4-trimethoxymethylpyridine 、 4-氨基-3-羟基苯甲酸 反应 0.08h， 生成 2-(4-pyridyl)-1,3-benzoxazole-6-carboxylic acid
  参考文献：
  名称：

  Benzoxazole and benzothiazole amides as novel pharmacokinetic enhancers of HIV protease inhibitors

  摘要：

  A new class of benzoxazole and benzothiazole amide derivatives exhibiting potent CYP3A4 inhibiting properties was identified. Extensive lead optimization was aimed at improving the CYP3A4 inhibitory properties as well as overall ADME profile of these amide derivatives. This led to the identification of thiazol-5-ylmethyl (2S,3R)-4-(2-(ethyl(methyl) amino)-N-isobutylbenzo[d]oxazole-6-carboxamido)-3-hydroxy-1-phenylbutan-2-ylcarbamate (C1) as a lead candidate for this class. This compound together with structurally similar analogues demonstrated excellent 'boosting' properties when tested in dogs. These findings warrant further evaluation of their properties in an effort to identify valuable alternatives to Ritonavir as pharmacokinetic enhancers. (c) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.022

文献信息

• [EN] PIPERAZINE DERIVATIVES AS MAGL INHIBITORS<br/>[FR] DÉRIVÉS DE PIPÉRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE MAGL
  申请人：HOFFMANN LA ROCHE

  公开号：WO2019072785A1

  公开（公告）日：2019-04-18

  The invention provides new heterocyclic compounds having general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

  这项发明提供了具有一般式（I）的新的杂环化合物，或其药用可接受的盐，其中R1、R2、X、Y1和Y2如本文所述，包括这些化合物的组合物，制造这些化合物的方法以及使用这些化合物的方法。
• METHODS FOR TREATING SPINAL MUSCULAR ATROPHY
  申请人：Paushkin Sergey V.

  公开号：US20110086833A1

  公开（公告）日：2011-04-14

  The present invention provides nucleic acid constructs, methods for identifying and validating compounds that increase the inclusion of exon 7 of SMN2 into mRNA transcribed from the SMN2 gene, compounds and pharmaceutical compositions that increase levels of SMN protein produced from the SMN2 gene, and methods for use thereof in treating of SMA.

  本发明提供了核酸构建物，用于识别和验证增加SMN2基因转录的mRNA中exon 7包含量的化合物的方法，增加从SMN2基因产生的SMN蛋白水平的化合物和药物组合物，以及在SMA治疗中使用它们的方法。
• Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases
  申请人：Wilde Richard

  公开号：US20080269191A1

  公开（公告）日：2008-10-30

  The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

  本发明涉及使用本发明的化合物或组合物治疗或预防与mRNA中无意义突变相关的疾病的方法、化合物和组合物。更具体地，本发明涉及用于抑制与mRNA中无意义突变相关的早期翻译终止的方法、化合物和组合物。
• METHODS FOR THE PRODUCTION OF FUNCTIONAL PROTEIN FROM DNA HAVING A NONSENSE MUTATION AND THE TREATMENT OF DISORDERS ASSOCICATED THEREWITH
  申请人：Almstead Neil G.

  公开号：US20110046136A1

  公开（公告）日：2011-02-24

  The present invention relates to functional proteins encoded by nucleic acid sequences comprising a nonsense mutation. The present invention also relates to methods for the production of functional proteins encoded by nucleic acid sequences comprising a nonsense mutation and the use of such proteins for prevention, management and/or treatment of diseases associated with a nonsense mutation(s) in a gene.

  本发明涉及由核酸序列编码的功能性蛋白质，其中包括一个无意义突变。本发明还涉及用于生产由包含无意义突变的核酸序列编码的功能性蛋白质的方法，以及利用这些蛋白质预防、管理和/或治疗与基因中的无意义突变相关的疾病。
• Compounds, Compositions and Methods for Stabilizing Transthyretin and Inhibiting Transthyretin Misfolding
  申请人：Labaudinière Richard

  公开号：US20110092545A1

  公开（公告）日：2011-04-21

  Compounds, compositions and methods are provided for stabilizing transthyretin and for treating, preventing, or ameliorating one or more symptoms of transthyretin mediated diseases. In one embodiment, the compounds are benzoxazoles and related compounds.

  提供了稳定甲状腺素转运蛋白和治疗、预防或改善甲状腺素转运蛋白介导疾病的复合物、组合物和方法。在一种实施例中，化合物是苯并噁唑和相关化合物。